Bing

Nearly a month after that Celgene deal, Juno's stock has remained relatively steady between about $49 and $54. The stock spiked high in after-hours trading the day the deal was announced (June 29), to $77 but then settled and opened the following day at ...
The Business Journal · 7/22/2015
A key contributor to Celgene's outsize stock performance this year has been investor read-through from management's confidence on hitting near-and long-term financial metrics. Investors should not be surprised to have management be similarly bullish on ...
istock Analyst · 1/8/2014
Biotechnology giant Celgene Corp. said Wednesday that a drug it was testing for a particular type of arthritis failed to reach its goals, but the news seemed to have little effect on the company’s stock price. Instead of falling, Celgene /quotes/zigman ...
Market Watch Commentary · ByRuss Britt · 7/9/2014
To look at Celgene Corp.'s stock chart in recent months is to think that you are back in 2000, when the sky was the limit for biotechnology stocks. The stock price of this Summit, N.J., cancer-treatment developer has jumped nearly 30 percent in the past ...
Pittsburgh Post-Gazette · 4/6/2006
Celgene Corporation (NASDAQ:CELG ... for all issued and outstanding shares of common stock of Receptos, Inc. (NASDAQ:RCPT) at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes and subsequent ...
Stockhouse · 8/11/2015
SUMMIT, N.J. (AP) -- Celgene Corp. said Wednesday that its board approved the repurchase of up to $3 billion in company stock. The biotech drugmaker said it has bought back $1.8 billion in stock this year, completing a $2.5 billion repurchase authorization.
Yahoo News · 6/12/2013
The board of directors for Celgene Inc. has authorized an additional stock repurchase of up to $3 billion, news that comes the same day the Summit-based biotech reported “meaningful improvements” on an investigational drug for psoriatic arthritis.
NJBIZ · 6/12/2013
In exchange for options to take partial license to Juno products, Celgene is paying $150 million upfront and buying $850 million in Juno stock at $93 per share, roughly double the stock’s closing price today. [Updated with comments from Celgene and Juno ...
Xconomy · 6/29/2015
Celgene Corp. will make an initial payment of about $1 billion, including a stock purchase, as part of a 10-year collaboration with fellow biotech company Juno Therapeutics Inc. on cancer and autoimmune disease treatments. In after-hours trading ...
Fox Business · 6/29/2015
Celgene said yesterday that its board of directors has authorized the repurchase of up to an additional $2 billion of the company’s common stock. The Summit-based company, which sells the cancer drugs Thalomid and Revlimid, is the state’s largest ...
New Jersey Online · BySusan Todd · 8/18/2011

Celgene

Company
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. I…
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid, which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum, as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid, for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate …
Data from: Wikipedia